135 related articles for article (PubMed ID: 19890502)
1. An update on gene therapy programs.
Romano G
Drug News Perspect; 2009 Sep; 22(7):435-40. PubMed ID: 19890502
[TBL] [Abstract][Full Text] [Related]
2. An overview on gene therapy programs.
Romano G
Drug News Perspect; 2008; 21(6):345-51. PubMed ID: 18836593
[TBL] [Abstract][Full Text] [Related]
3. The standpoint of gene therapy programs.
Romano G
Drug News Perspect; 2007 Jun; 20(5):335-43. PubMed ID: 17878962
[TBL] [Abstract][Full Text] [Related]
4. A call for physiopathological ethics.
Lowenstein PR
Mol Ther; 2008 Nov; 16(11):1771-2. PubMed ID: 18956015
[No Abstract] [Full Text] [Related]
5. Advances and perspectives in the field of gene transfer technology.
Romano G
Drug News Perspect; 2006; 19(6):359-68. PubMed ID: 16971973
[TBL] [Abstract][Full Text] [Related]
6. Current development of adeno-associated viral vectors.
Romano G
Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with adenovirus in cancer therapy.
Palmer DH; Mautner V; Kerr DJ
Curr Opin Mol Ther; 2002 Oct; 4(5):423-34. PubMed ID: 12435043
[TBL] [Abstract][Full Text] [Related]
8. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated viral vectors for Parkinson's disease.
Muramatsu S; Wang L; Ikeguchi K; Fujimoto K; Nakano I; Okada T; Mizukami H; Hanazono Y; Kume A; Nakano I; Ozawa K
Int Rev Neurobiol; 2003; 55():205-22. PubMed ID: 12968538
[No Abstract] [Full Text] [Related]
10. Lentiviral vector-based gene therapy in Parkinson disease.
Richardson M
Neurosurgery; 2014 Jun; 74(6):N11-2. PubMed ID: 24836099
[No Abstract] [Full Text] [Related]
11. The role of cis-regulatory elements in the design of gene therapy vectors for inherited blindness.
Corbo JC
Expert Opin Biol Ther; 2008 May; 8(5):599-608. PubMed ID: 18407764
[TBL] [Abstract][Full Text] [Related]
12. Parkinson disease: Another player in gene therapy for Parkinson disease.
Kaplitt MG
Nat Rev Neurol; 2010 Jan; 6(1):7-8. PubMed ID: 20057491
[No Abstract] [Full Text] [Related]
13. Adeno-associated virus vectors for therapeutic gene transfer.
Stilwell JL; Samulski RJ
Biotechniques; 2003 Jan; 34(1):148-50, 152, 154 passim. PubMed ID: 12545552
[No Abstract] [Full Text] [Related]
14. Gene therapy for blindness.
Sahel JA; Roska B
Annu Rev Neurosci; 2013 Jul; 36():467-88. PubMed ID: 23724995
[TBL] [Abstract][Full Text] [Related]
15. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for inherited blindness shows promise in first clinical trial.
Torjesen I
BMJ; 2014 Jan; 348():g269. PubMed ID: 24435417
[No Abstract] [Full Text] [Related]
17. Success against blindness encourages gene therapy researchers.
Ledford H
Nature; 2015 Oct; 526(7574):487-8. PubMed ID: 26490597
[No Abstract] [Full Text] [Related]
18. Parkinson's disease gene therapy: success by design meets failure by efficacy.
Bartus RT; Weinberg MS; Samulski RJ
Mol Ther; 2014 Mar; 22(3):487-497. PubMed ID: 24356252
[TBL] [Abstract][Full Text] [Related]
19. [Adenovirus vectors and their clinical application in gene therapy].
Adám E; Nász I
Orv Hetil; 2001 Sep; 142(38):2061-70. PubMed ID: 11697063
[TBL] [Abstract][Full Text] [Related]
20. 11th annual congress of the European Society of Gene Therapy.
Read ML; Logan A
Expert Rev Anticancer Ther; 2004 Feb; 4(1):49-51. PubMed ID: 14748656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
